LESI Announces the 2011-2012 Board of Directors
LES International Board of Delegates Announces the 2011-2012 Board of Directors. President: James E. Malackowski President Elect: Kevin Nachtrab Past President: Alan Lewis Treasurer: James Sobieraj Secretary: John Walker Joint Counsels: Jean-Christophe TrousselFrancois Painchaud Vice Presidents: Arnaud MichelPaul GermeraadPatricia BunyeHector Chagoya
A Review Of The Global BioPharmaceutical Royalty Rates And Deal Terms Survey: Licensing Executives Society (U.S.A. And Canada), Inc. And Licensing Executives Society International (LESI)
James A. McCarthyCLP Head of Corporate Development, Asklepion Pharmaceuticals, LLC, Baltimore, Maryland Ben BonifantPractice Area Leader Campbell Alliance, Raleigh, NC, USA Licensing thrives within the life sciences industry. Each year, thousands of transactions transferring intellectual property rights are negotiated among hundreds of parties. These deals support a system in which organizations with vastly different resources, […]
Incentives For Generating More IP Commercialization Opportunities
Henry FradkinValue Extraction, LLC, Principal, Dearborn, MI, USA I don’t think I have to belabor the point… this is really a tough economy. Based on at least what I am seeing and echoed by others in the IP and technology commercialization business, it appears that most “licensing” deals are the result of successful patent assertions […]
Bridging The Gap For Public Good: A Study On The Mission Statements Of U.S. University Technology Transfer Programs
Seok-Ho KimNational Research Foundation of Korea, Senior Researcher, Korea Alan S. PaauCornell University , Vice Provost & Executive Director, Ithaca, NY, USA The year 2010 marks the thirtieth anniversary of the passage of the Bayh-Dole Act of 1980 (the “Act”), which later became part of the U.S. patent Law (35 United States Code). The Act […]
The Project For A Uniform European Union (EU) Patent And A Unified Patent Litigation System Within The EU: Closer Than Ever, But With Some Detractors
José Miguel LissénIP Litigator, Senior Associate, Gómez-Acebo & Pombo, Abogados, S.L.P., Madrid, Spain Sergio PozaIP Litigator, Associate, Gómez-Acebo & Pombo Abogados, S.L.P. , Abogado, Madrid, Spain In Europe, patent protection granted by the national patent systems through an application filed with the national patent office coexists with the protection granted by the so-called European Patent […]
IPR-Codes And Guidelines In Europe Facilitating Collaboration Of Publicly Funded Research Organizations (PROs) With Businesses Part 1
Thomas L. BereuterGraz University of Technology, Vienna, Austria David JerolitschCEST, Wiener Neustadt, Austria Peter G. HeimerlVienna University of Technology, Vienna, Austria Effective and efficient technology transfer by collaborative R&D between universities or other publicly-funded organizations and businesses is rewarding and necessary, but a challenge. Negotiation of the terms for the collaboration often proves to be […]
A Simple Method For Calculating A “Fair” Royalty Rate
Damien SalauzeInstitut Curie VP, Business Development & Licensing, Paris, France During a licensing deal (i.e. license of a patent protecting a product), several methods are commonly used to determine what is intended to be a “fair” royalty rate. It is even recommended to combine several methods in order to cross-check that there is no discrepancy […]
License Compliance Issues For Biopharmaceuticals: Special Challenges For Negotiations Between Companies And Non-Profit Research Institutions
Todd A. PonzioPhD, National Cancer Institute Technology Transfer, Fellow, Rockville, MD, USA Hans FeindtPhD, NIH Office of Technology Center, Chief, Monitoring and Enforcement Branch, Rockville, MD, USA Steven FergusonCLP, NIH Office of Technology Transfer, Deputy Director, Licensing & Technology Transfer, Rockville, MD, USA Biopharmaceuticals are therapeutic products based on biotechnology. They are manufactured by or […]
Holding Patents Hostage? The Need For HIV/AIDS Drugs In Poor Countries Threatens The Health Of International Patent Protection
Elizabeth Durham On June 24 of 2005, the Brazilian government enacted legislation that would override Abbott Laboratories’ patent on Kaletra®, an anti-retroviral drug used to treat HIV and AIDS, and would enable generic production and sale of the drug at nearly half the price that Abbott currently charges. Abbott was given ten days from that […]
Backing Up The Claim: Reverse Engineering Enables Successful Patent Licensing
Terry LudlowChipworks Founder, Chairman and CEO, Ottawa, Canada Mike ThummChipworks, VP Patent Intelligence, Ottawa, Canada Andrea GironesPatent Advisor to Chipworks, Ottawa, Canada Intellectual Property licensing is becoming a key aspect of leading corporations’ strategic business plans. And, finding and proving infringement of your patents is the essential foundation of any successful licensing campaign. More and […]
